Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdMSC and Secretome for PCL Regeneration
NCT04889963Phase 1Unknown
- Sponsor
- Universitas Gadjah Mada
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of CSCC_ASC in posterior cruciate ligament rupture (4 arms), sponsored by Universitas Gadjah Mada. Primary endpoints: Tensile Strength of Posterior Cruciate Ligament at 6 weeks, Thrombosite of Growth Factor - beta 1 at 6 weeks and 1 more. Status: unknown.
02
Drugs
CSCC_ASC
03
Conditions
posterior cruciate ligament rupture
Beyond the preview
Go deeper on NCT04889963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889963.